TITLE

Clinic Roundup

PUB. DATE
March 2011
SOURCE
BioWorld Today;3/10/2011, Vol. 22 Issue 47, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs related to biotechnology firms as of March 2011, including the submission of an investigational new drug application to the U.S. Food and Drug Administration (FDA) by Adamis Pharmaceuticals Corp., the status of Auxilium Pharmaceutical Incorporated's study of Xiaflex for Peyronie's disease, and the enrollment of the first group of patients in the Phase I/II trial of NeuroDerm Limited's dermal patch ND0611.
ACCESSION #
59257328

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;8/31/2011, Vol. 22 Issue 169, p4 

    The article discusses the first patient enrolled by Adamis Pharmaceuticals Corp. for its Phase I/IIa study of a signal transduction inhibitor, oral anti-androgenic/anti-inflammatory called APC-100 for men who have castrate-resistant prostate cancer.

  • Clinic Roundup.  // BioWorld Today;3/26/2013, Vol. 24 Issue 59, p4 

    This section offers news briefs concerning drug clinical trials. Auxilium Pharmaceuticals Inc. reported positive data from the Phase IIa open-label study of Xiaflex therapeutic safety in adhesive capsulitis. OncoSec Medical Inc. posted positive response results from its Phase II clinical trial...

  • CLINIC ROUNDUP.  // BioWorld Today;5/23/2007, Vol. 18 Issue 100, p3 

    The article offers news briefs on clinical trials. Improvements in symptoms of decreased libido and erectile dysfunction in hypogonadal men were reported by Auxilium Pharmaceuticals Inc. in a retrospective data reported at an American Urological Association meeting. A phase I-data showing...

  • FDA Approves Trial of Adamis Pharmaceuticals Product Candidate to Treat Prostate Cancer.  // Biomedical Market Newsletter;6/9/2011, p84 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Adamis Pharmaceuticals Corp.'s investigational new drug (IND) application for its APC-100 prostate cancer (PCa) treatment. It states that the company plans to start its Phase 1/2a clinical studies of APC-100 in...

  • Adamis Prostate Cancer Drug APC-100 Receives Allowance for Patent in Canada.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p164 

    The article reports on the Notice of Allowance received by Adamis Pharmaceuticals Corp. for the technology that constitutes its compound APC-100 for the patent application in Canada. It states that the APC-100 is part of the Phase 1/2a clinical prostate trial at the University of Wisconsin...

  • XIAFLEX EFFECTIVE IN NONSURGICALLY TREATING MP/PIP JOINTS.  // Worldwide Biotech;Jan2011, Vol. 23 Issue 1, p6 

    This article reports on the publication of the pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) conducted by Auxilium Pharmaceuticals Inc. in 2010. The company announced the publication of the trial in the December 2010 online edition of "The Journal of...

  • Clinic Roundup.  // BioWorld Today;9/7/2011, Vol. 22 Issue 173, p9 

    This section offers news briefs related to clinical trials. AB Science SA of Paris, France recruited the first patient in a study of protein kinase inhibitor masitinib in a primary progressive multiple sclerosis. AiCuris GmbH & Co. of Germany said that a resistance analysis from a trial of...

  • PROs, Cons in Peyronie's Effort: Bending Auxilium Out of Shape. Osborne, Randy // BioWorld Insight;12/21/2009, Vol. 17 Issue 51, p2 

    The article reports on the assessment made by the U.S. Food and Drug Administration (FDA) before unveiling its ideas on patient-reported outcome (PRO) measures. It discusses the findings of a 36-week, 145-patient double-blind study conducted by Auxilium Pharmaceuticals Inc. regarding Peyronie's...

  • Clinic Roundup.  // BioWorld Today;2/ 5/2013, Vol. 24 Issue 24, p8 

    The article offers news briefs related to biopharmaceutics as of February 5, 2013. Auxilium Pharmaceuticals Inc. has already published its pivotal Phase III IMPRESS' uncorrected proof in "The Journal of Urology." The ininterim analysis of BioLineRx Ltd.'s Phase II/III CLARITY trial for BL-1020...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics